BRIEF-Denali Therapeutics Announces Initiation Of BLA Filing For Accelerated Approval Of Tividenofusp Alfa For Treatment Of Hunter Syndrome

Reuters

04-02

BRIEF-Denali <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Announces Initiation Of BLA Filing For Accelerated Approval Of Tividenofusp Alfa For Treatment Of Hunter Syndrome

April 2 (Reuters) - Denali Therapeutics Inc DNLI.O:

DENALI THERAPEUTICS ANNOUNCES INITIATION OF BLA FILING FOR ACCELERATED APPROVAL OF TIVIDENOFUSP ALFA FOR TREATMENT OF HUNTER SYNDROME (MPS II) AND POSITIVE ONGOING INTERACTIONS WITH FDA ON DNL126 THROUGH START PROGRAM
DENALI THERAPEUTICS : EXPECTS TO COMPLETE BLA SUBMISSION IN FIRST HALF OF MAY 2025
DENALI THERAPEUTICS INC: CONTINUES TO PREPARE FOR A POTENTIAL COMMERCIAL LAUNCH IN U.S. IN LATE 2025 OR EARLY 2026

Source text: ID:nGNX7SFxct

Further company coverage: DNLI.O

(((( Reuters.briefs@thomsonreuters.com ;));))

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2524673924"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2524673924\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2524673924?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-04-02 20:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2524673924","market":"nz","top_or_hot":-1,"title":"BRIEF-Denali Therapeutics Announces Initiation Of BLA Filing For Accelerated Approval Of Tividenofusp Alfa For Treatment Of Hunter Syndrome","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Denali <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Announces Initiation Of BLA Filing For Accelerated Approval Of Tividenofusp Alfa For Treatment Of Hunter Syndrome</title></head><body><p><span>April 2 (Reuters)</span><span> - </span>Denali Therapeutics Inc <span>DNLI.O</span>:</p><ul><li><p>DENALI THERAPEUTICS ANNOUNCES INITIATION OF BLA FILING FOR ACCELERATED APPROVAL OF TIVIDENOFUSP ALFA FOR TREATMENT OF HUNTER SYNDROME (MPS II) AND POSITIVE ONGOING INTERACTIONS WITH FDA ON DNL126 THROUGH START PROGRAM</p></li><li><p>DENALI THERAPEUTICS : EXPECTS TO COMPLETE BLA SUBMISSION IN FIRST HALF OF MAY 2025</p></li><li><p>DENALI THERAPEUTICS INC: CONTINUES TO PREPARE FOR A POTENTIAL COMMERCIAL LAUNCH IN U.S. IN LATE 2025 OR EARLY 2026</p></li></ul><p>Source text: <span>ID:nGNX7SFxct</span></p><p>Further company coverage: <span>DNLI.O</span></p><p> (((( Reuters.briefs@thomsonreuters.com ;));))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Denali Therapeutics Announces Initiation Of BLA Filing For Accelerated Approval Of Tividenofusp Alfa For Treatment Of Hunter Syndrome</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Denali Therapeutics Announces Initiation Of BLA Filing For Accelerated Approval Of Tividenofusp Alfa For Treatment Of Hunter Syndrome\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-04-02 20:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Denali <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Announces Initiation Of BLA Filing For Accelerated Approval Of Tividenofusp Alfa For Treatment Of Hunter Syndrome</title></head><body><p><span>April 2 (Reuters)</span><span> - </span>Denali Therapeutics Inc <span>DNLI.O</span>:</p><ul><li><p>DENALI THERAPEUTICS ANNOUNCES INITIATION OF BLA FILING FOR ACCELERATED APPROVAL OF TIVIDENOFUSP ALFA FOR TREATMENT OF HUNTER SYNDROME (MPS II) AND POSITIVE ONGOING INTERACTIONS WITH FDA ON DNL126 THROUGH START PROGRAM</p></li><li><p>DENALI THERAPEUTICS : EXPECTS TO COMPLETE BLA SUBMISSION IN FIRST HALF OF MAY 2025</p></li><li><p>DENALI THERAPEUTICS INC: CONTINUES TO PREPARE FOR A POTENTIAL COMMERCIAL LAUNCH IN U.S. IN LATE 2025 OR EARLY 2026</p></li></ul><p>Source text: <span>ID:nGNX7SFxct</span></p><p>Further company coverage: <span>DNLI.O</span></p><p> (((( Reuters.briefs@thomsonreuters.com ;));))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"DNLI","symbol_name":"Denali Therapeutics Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250402:nFWN3QG0CX:1","article_id":"2524673924","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2524673924","pubTimestamp":1743595367,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Denali Therapeutics Announces Initiation Of BLA Filing For Accelerated Approval Of Tividenofusp Alfa For Treatment Of Hunter SyndromeApril 2 (Reuters) - Denali Therapeutics Inc DNLI.O:DENALI THE","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"DNLI":"Denali Therapeutics Inc.","BK4535":"淡马锡持仓","BK4548":"巴美列捷福持仓","BK4139":"生物科技"},"translate_title":"简介-Denali Therapeutics宣布启动BLA备案，以加速批准Tividenofusp Alfa用于治疗亨特综合征","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DNLI":0.9},"content_text":"BRIEF-Denali Therapeutics Announces Initiation Of BLA Filing For Accelerated Approval Of Tividenofusp Alfa For Treatment Of Hunter SyndromeApril 2 (Reuters) - Denali Therapeutics Inc DNLI.O:DENALI THERAPEUTICS ANNOUNCES INITIATION OF BLA FILING FOR ACCELERATED APPROVAL OF TIVIDENOFUSP ALFA FOR TREATMENT OF HUNTER SYNDROME (MPS II) AND POSITIVE ONGOING INTERACTIONS WITH FDA ON DNL126 THROUGH START PROGRAMDENALI THERAPEUTICS : EXPECTS TO COMPLETE BLA SUBMISSION IN FIRST HALF OF MAY 2025DENALI THERAPEUTICS INC: CONTINUES TO PREPARE FOR A POTENTIAL COMMERCIAL LAUNCH IN U.S. IN LATE 2025 OR EARLY 2026Source text: ID:nGNX7SFxctFurther company coverage: DNLI.O (((( Reuters.briefs@thomsonreuters.com ;));))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"code":"91000000","status":"200"}}}